港股健倍苗苗（02161）今日盘中大涨5.78%，引发市场广泛关注。截至发稿，该股报价为2.84港元，成交额达400.42万港元。
此次股价上涨主要受两大利好因素推动。首先，健倍苗苗于6月12日发布的2025财年年度业绩表现亮眼。公司公布截至2025年3月31日止年度的财报显示，集团收益达7.82亿港元，同比增长20.65%；公司权益持有人应占溢利更是大幅增长51.2%，达到1.97亿港元。每股盈利为24.08港仙，公司拟派末期股息每股11.5港仙。这一优异业绩主要得益于公司旗舰品牌何济公、保济丸及飞鹰活络油的显著增长，以及浓缩中药颗粒业务的稳定贡献。
其次，健倍苗苗宣布了一项战略性收购计划，拟以3800万港元收购健福堂中医集团全部股权。健福堂中医集团主要从事提供中医诊症服务及销售健康产品。这次收购为健倍苗苗带来了战略性机遇，有助于公司把握传统中药及预防性健康解决方案需求持续增长的趋势。通过此次收购，健倍苗苗将能够利用健福堂中医集团广泛的诊所网络，扩大其浓缩中药颗粒的分销基础，并进一步释放品牌中药产品组合的增长潜力。市场普遍认为，这一战略举措将为公司未来业绩增长注入新的动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.